This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Power for Ancient Names in Biotech

NEW YORK (TheStreet) -- Watching Jim Cramer last Friday on "Mad Money" reminded me of some of the darlings in the biotech and biopharmaceutical space with fascinating names and powerful momentum.

Gilead, for example, is a Hebrew word which means "Hill of testimony" or "mound of witness." As a child my family loved to sing an old spiritual song called "There is a Balm in Gilead." A "balm" is a healing or soothing substance, and there's a publicly traded company named Gilead Sciences (GILD) that's been working on some life-saving "balms" worth billions of dollars.

GILD is a biopharmaceutical company with a $51.40 billion market cap that discovers, develops, and commercializes human therapeutics for the treatment of life-threatening diseases all over the planet. Its product list reads like a "Who's Who" or "What's What" of the world of pharmaceutical products.

They include Atripla, Truvada, Viread, Complera/Eviplera and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; Viread and Hepsera oral formulations for the treatment of chronic hepatitis B; Letairis, an oral formulation for pulmonary arterial hypertension; Ranexa, a tablet for chronic angina; Lexiscan/Rapiscan, a test that detects and characterizes coronary artery disease; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, a capsule for the treatment and prevention of influenza A and B.

Their trailing-12-months revenue is more than $9 billion and they have a product pipeline in various stages of testing and development slated to make them billions more. Rather than repeat what Cramer said about this popular company, I'll show you the following chart and you can see for yourself that it's been experiencing major accumulation.

GILD ChartGILD data by YCharts
Since April 2012 the profit margin has ascended impressively as has the price-per-share.

On Monday, Oct. 15, some good news for Abbott Labs (ABT) cast more positive light on what appears to be coming down the pipeline for Gilead Sciences concerning its hepatitis treatments.

ABT reported that its experimental hepatitis C drug regimen cured 99% of patients in a middle-stage study with the most common and most difficult form of the disease. This news alone caused share of ABT to leap more than 3% to hit an intra-day, 52-week high of $71.99!

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs